Clinical Feasibility of Disease-managing Mobile Application in the Patients With Hyperthyroidism
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hyperthyroidism
- Sponsor
- Seoul National University Bundang Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Scores of quality of life assessed by SF-36 survey
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This randomized controlled study aims to investigate the effects of using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. The study intends to evaluate how the use of the app affects disease progression, quality of life, and health-related behaviors associated with the disease.
Investigators
Jae Hoon Moon
Professor
Seoul National University Bundang Hospital
Eligibility Criteria
Inclusion Criteria
- •Subjects who have been newly diagnosed or are currently undergoing treatment for thyrotoxicosis at Bundang Seoul National University Hospital.
- •Subjects must be able to use the smartphone app required for the use of wearable devices and their integration.
Exclusion Criteria
- •Subjects who have constraints on normal activity due to diseases other than thyroid dysfunction.
- •Subjects who are currently taking medication that affects heart rate.
- •Subjects with heart conditions such as arrhythmia that affect heart rate.
- •Subjects who cannot undergo antithyroid drug treatment and require surgery or radioactive iodine therapy.
Outcomes
Primary Outcomes
Scores of quality of life assessed by SF-36 survey
Time Frame: 14 weeks after baseline
Scores of quality of life assessed by SF-36 survey
antithyroidal drug compliance
Time Frame: 14 weeks after baseline
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
Knowledge about hyperthyroidism
Time Frame: 14 weeks after baseline
A score measured through a test designed to assess the knowledge level about Graves' disease
Secondary Outcomes
- free T4(14 weeks after baseline)
- free T3(14 weeks after baseline)
- TSH(14 weeks after baseline)